Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $491.27 Consensus PT from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average rating of “Reduce” from the fifteen research firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $491.2727.

MEDP has been the topic of several analyst reports. Truist Financial set a $555.00 price objective on Medpace in a research note on Monday, October 27th. Barclays increased their price objective on Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. TD Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 target price on the stock. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th.

Insider Activity

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the completion of the transaction, the chief executive officer directly owned 774,602 shares in the company, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 387,925 shares of company stock worth $233,386,647. Insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MEDP. Quent Capital LLC bought a new stake in Medpace during the 3rd quarter worth about $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace during the third quarter valued at $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace during the 4th quarter worth about $30,000. Quarry LP bought a new position in shares of Medpace in the 3rd quarter valued at about $35,000. Finally, Root Financial Partners LLC acquired a new stake in shares of Medpace during the 3rd quarter worth approximately $38,000. 77.98% of the stock is owned by institutional investors.

Medpace Stock Performance

Shares of Medpace stock opened at $588.05 on Thursday. The firm has a market cap of $16.57 billion, a P/E ratio of 41.12, a price-to-earnings-growth ratio of 1.97 and a beta of 1.43. The firm’s 50-day simple moving average is $583.65 and its 200-day simple moving average is $521.26. Medpace has a twelve month low of $250.05 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.01 earnings per share. On average, equities analysts forecast that Medpace will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.